Introduction
effects described above are similar to those of anticholinergic drugs. An anticholinergic action has also been reported for morphine [9, 10] , which was found to The m-opiate receptor agonist loperamide is a widely used drug for symptomatic treatment of patients with suppress insulin-and meal-induced release of pancreatic polypeptide (PP), a hormone under vagal cholinergic diarrhoea [1 ] . Its antidiarrhoeal effect is primarily due to an inhibition of intestinal secretion and gut motility control [11] . The intention of this study was to examine the [ 2, 3 ] . Loperamide also inhibits basal and pentagastrinstimulated gastric acid secretion [4, 5 ] , meal-stimulated hypothesis, that m-opiate receptor agonists (like morphine and loperamide) display an anticholinergic action. pancreatic enzyme secretion [ 6] , and cholecystokinin (CCK)-induced gall bladder emptying [7 ] .
For this purpose, we investigated the effects of loperamide on PP release in man after vagal stimulation and The mode of action, however, has not been clearly defined. As loperamide hardly crosses the blood-brain after application of a peripheral acting cholinergic drug. We also examined the influence of loperamide on CCKbarrier, it presumably acts on peripheral m-opiate receptors [2, 8 ] . On the other hand, the inhibiting induced PP release, which is known to be blocked by atropine [ 12] . Bearing in mind that corticotropin Ceruletide inf usion The CCK analogue ceruletide (40 ng kg−1 body weight; TakusA, Farmitalia, Freiburg, releasing hormone (CRH ) can cause PP release in man [ 14] and CRH receptors are synthesized and transGermany) was infused intravenously over a 5 min period. Three hours before ceruletide infusion, either ported in the rat vagus nerve [ 13] , loperamide was also given before application of CRH. A preliminary report 2 mg, 6 mg, and 16 mg loperamide or placebo were applied orally. Similar to the procedure described in on the results was presented at the 27th Annual Meeting of the European Society for Clinical Investigation, MSF, in two additional series with 16 mg loperamide or placebo, 0.8 mg of the opiate antagonist naloxone Heidelberg, Germany, 1993, and published as an abstract [33 ] .
was injected intravenously 20 min before and immediately before infusion of ceruletide. In a further series, 3 h before ceruletide infusion, atropine was applied as described above.
Methods

Corticotropin releasing hormone (CRH ) injection
Synthetic human CRH (100 mg, Bissendorf Peptide, Subjects and test procedures Wedemark, Germany) was injected intravenously 3 h after oral application of 16 mg loperamide or of placebo. All tests described below were performed with groups of six young healthy males (aged 25-27 years). The test protocol was approved by the Ethics Committee of the Bethanechol inf usion Three hours after oral adminisMedical Faculty of the University of Munich. Each tration of 16 mg loperamide or of placebo, bethanechol subject gave written informed consent.
infusions (UrecholineA, Merck Sharpe & Dohme, Given orally, loperamide is absorbed slowly and peak Westpoint, PA, USA) were administered over 40 min plasma concentrations are reached 3-4 h after intake periods in gradually increasing doses (12.5, 25, [ 2] . Therefore, the drug was applied at least 3 h before and 50 mg kg−1 h−1). Heart rate, blood pressure and stimulating PP release. The highest dose given (16 mg) clinical symptoms of cholinergic stimulation were corresponds to the recommended maximum daily dose recorded. for treatment of diarrhoea. Blood samples for radioimmunological determination of PP were drawn frequently from a peripheral vein in ice-chilled 10 ml syringes Radioimmunoassay of pancreatic polypeptide Plasma (containing 37.1 mmol K 2 -EDTA). The samples were PP concentrations were measured with a radioimmunoimmediately centrifuged at 4°C and the plasma stored assay described previously [ 15] . The anti-porcine PP at −20°C.
antiserum (K5418, Novo, Copenhagen, Denmark) showed a cross-reactivity of >95 % with human PP and none with other gastroenteropancreatic peptides. Insulin-hypoglycaemia-test (IHT ) Three hours before
The detection limit of the PP assay was 1.1±0.3 p. starting an IHT, the subjects received either 16 mg
The intra-and inter-assay coefficients of variation were loperamide (ImodiumA, Janssen, Neuss, Germany) or 11.1% at 12.9 p and 13.1% at 14.3 p, respectively. placebo orally. The IHT was performed by intravenous injection of recombinant human insulin (0.15 iu kg−1 body weight, Actrapid HMA, Novo, Mainz, Germany). Hypoglycaemia was regarded as adequate, when blood Statistics and calculations glucose levels decreased to below 2.2 m and typical clinical symptoms were noted.
Changes of parameters were analysed by comparing the last value before stimulus application with those after stimulation using the Friedmann two-way analysis of Modified sham feeding (MSF) MSF was performed variance. Integrated peptide values were calculated as 5 h after oral intake of 2 mg, 6 mg, and 16 mg loperamthe areas under the concentration curves. The integrated ide, respectively, or after application of placebo. In each incremental responses (') were obtained by subtraction series, the subjects had to chew pieces of a roll with jam of the baseline levels. The integrated incremental over a 15 min period without swallowing. In order to responses of the different series were compared and investigate, whether the effect of loperamide is due to analysed with the U-test of Wilcoxon, Mann, and its opiate property, in another six subjects receiving Whitney. P≤0.05 was considered statistically significant. 16 mg loperamide or a placebo, respectively, 0.8 mg All values are given in mean±s.e. mean. naloxone (NarcantiA, DuPont Pharma, Bad Homburg, Germany) was injected intravenously, 20 min in advance and immediately before beginning of MSF. In a further series, MSF was performed 5 h after intravenous injection of 2.5 mg kg−1 body weight atropine (AtropinsulfatA, Braun, Melsungen, Germany) followed Results by an intravenous infusion of 5 mg kg−1 h−1 until the end of the experiment. Heart rate, blood pressure, and
In all tests, basal plasma PP levels were significantly reduced by 16 mg loperamide and by atropine, 3 h after clinical symptoms of cholinergic blockade were recorded.
application. The values were also significantly lower than in the placebo series.
Insulin-hypoglycaemia-test
The IHT caused a marked and long-lasting augmentation of plasma PP concentrations from 3.9±1.0 to 102.6±14.7 p. The increase was prevented by loperamide (peak concentration 10.9±4.1 p). Accordingly, IHT-induced incremental integrated plasma PP was significantly suppressed by loperamide ( Figure 1 ).
Modified sham feeding
After placebo, MSF caused a prompt rise of plasma PP levels to a peak of 48.8±7.2 p at 15 min. After 2 and 6 mg loperamide, this increase was significantly reduced (peaks of 31.1±10.9 and 13.5±5.5 p) and after 16 mg it was nearly nullified (5.5±1. 
Ceruletide
Ceruletide caused a steep rise of plasma PP levels to a peak of 103.2±21.3 p at 7.5 min in the placebo series. The effect was significantly and dose-dependently reduced by 2 and 6 mg loperamide and almost negated by 16 mg loperamide (59.1±10.4, 33.3±7.6, and 8.0±1.3 p, respectively). The blockade of PP release by 16 mg loperamide was partly but significantly reversed by naloxone (51.4±13.5 p). Naloxone alone, however, did not influence ceruletide-induced PP increase (112.9±27.3 p).
Integrated plasma PP was significantly increased by ceruletide in all series, except after 16 mg loperamide (Figure 4 ). Incremental integrated plasma PP was 
Corticotropin releasing hormone (CRH) injection
Intravenous injection of 100 mg CRH caused a prompt and significant rise of plasma PP concentrations to a peak value of 21.6±7.4 p. The increase was nearly nullified by 16 mg loperamide (3.4±1.1 p). Accordingly, incremental integrated plasma PP was also significantly suppressed (713±344 vs 66±25 pmol l−1 120 min; P=0.01). PP after loperamide remained significantly below those after placebo, but the difference in increases did not significantly differ (values at the end of the highest dose of bethanechol: 19.0±7.8 vs 18.7±5.0 p). Accordingly, incremental integrated plasma PP values were not significantly different ( Figure 5 ). Side effects (salivation, sweating, mild abdominal gripe, and need to pass water) occurred during the infusion of the high dose of bethanechol with and without loperamide to a comparable extent. from a small increase of heart rate during atropine Discussion stimulated PP release may be mediated by binding of these peptides to afferent sensory vagal fibres followed by central activation of efferent vagal cholinergic fibres. PP is a hormone under vagal cholinergic control [11 ] . PP release induced by an IHT in man is suppressed by
Bethanechol infusion
In the cat m-opiate receptors have been detected in presynaptical parts of vagal afferents terminating within morphine [ 9] . We observed a similar suppressive effect for the m-opiate receptor agonist loperamide. Apart a restricted region of the nucleus of the tractus solitarius [25] . Furthermore, m-opiate receptors are also found from the suppressive effect on IHT-induced PP release, it was shown for the first time that loperamide also on capsaicin-sensitive afferent vagal fibres [26 ] and on dorsal spinal root fibres [27] of the rat. Therefore, counteracts PP release induced by MSF, ceruletide, and CRH. In contrast, PP release stimulated by the muscarbinding of loperamide to opiate receptors on afferent vagal fibres might block impulses elicited by CCK. inergic agonist bethanechol was not influenced.
In adults, 60 mg loperamide is the threshold dose for CCK applied in a pharmacological dose to prelabelled rat pancreatic lobules caused a release of [3H]-producing side effects [16 ] . Accordingly, no side effects of loperamide were observed in our study (maximal acetylcholine [ 28] and most probably also caused PP release. PP, however, was not monitored in this study. dose applied was 16 mg).
The IHT is an established procedure to stimulate Thus, an additional inhibitory action of loperamide on intrapancreatic cholinergic neurones cannot be ruled out. vagal cholinergic mechanisms [17 ] . The concomitant PP release [ 11] is independent of adrenergic mechan-CRH applied in a pharmacological dose has also been shown to cause PP release [14 ] . We confirmed isms [18 ] . The IHT performed in this study caused a marked and long-lasting PP release, which was prethis finding, but the peak plasma PP concentrations were distinctly lower than those obtained with ceruletide. vented by 16 mg loperamide. PP release stimulated by MSF was completely blocked by 16 mg loperamide. The
We can only speculate on the mode of action of CRH.
Vagal pathways may be involved as CRH receptors effect was comparable with that of atropine. Moreover, the suppressive effect of loperamide on MSF-induced have been found to be present in the vagus nerve of the rat [13 ] . The suppression of CRH-induced PP release PP release was dose-dependent. As both IHT-and MSF-induced PP release is blunted by vagotomy [19 ] , by loperamide shown in our study also points to the vagus nerve as a target of loperamide. central vagal stimulation and efferent vagal fibres seem to be involved. Therefore, loperamide may exert its
No data are available concerning the action of m-opiate receptor agonists on the PP-producing F cells. inhibitory action on efferent vagal pathways. It cannot be ruled out, however, that central vagal structures may Therefore, bethanechol, an acetylcholine analogue binding to muscarinic receptors only, was applied in order also represent a target of loperamide, as traces of the drug can be detected in the brain [2 ] . A direct action to stimulate PP release at the cellular level. Bethanechol caused a dose-dependent increase of plasma PP which of loperamide on the PP-producing F cells of the pancreas can be excluded.
was not influenced by loperamide. Therefore, this drug does not exert an atropine-like peripheral anticholi-PP release induced by physiological doses of CCK or CCK analogues, like ceruletide, is dependent on cholnergic action. We conclude from these results that loperamide exerts inergic pathways, since it can be blocked by atropine [ 12] . In our study, infusion of a pharmacological dose its inhibitory action on PP release via afferent and efferent vagal pathways. An additional action on central of ceruletide caused a significant rise of plasma PP concentrations -comparable with post-prandial peak vagal structures or on intrapancreatic cholinergic neurons and on enteropancreatic cholinergic pathways concentrations [20] -and of integrated PP. This PP release was dose-dependently inhibited by loperamide. cannot be ruled out. As basal PP release is dependent on a vagal cholinergic tone [ 11, 29] , the suppressive Atropine used in a dose sufficient to inhibit acetylcholine-mediated gastrointestinal functions [21 ] exerted a effect of loperamide on basal PP levels shown in this study also indicates that vagal pathways may be certain suppressive effect on ceruletide-induced PP release similar to 6 mg loperamide, but did not negate involved.
The mechanisms of the inhibitory action of loperamide it completely. In a previous study [12] using the same dose of atropine, ceruletide-induced PP release was on PP release have not yet been investigated. In the present study, naloxone, a central and peripheral acting blunted. The dose of ceruletide applied was lower than in our study, as verified by peak plasma levels of CCKmorphine antagonist attenuated loperamide-induced suppression of MSF-and ceruletide-stimulated PP like immunoreactivity (approximately 20 p vs 233±43 p; personal observation). On the other hand, 16 mg release. The effect did not seem to be a matter of dosage. Using the same doses of loperamide (16 mg) and loperamide completely blocked the PP response to the pharmacological dose of ceruletide applied in our study.
naloxone (1.6 mg) as in this study, we were able to show that the inhibitory action of loperamide on ceruletideIn rats, expression and transport of CCK receptors in vagal fibres has been shown recently [22 ] . Furthermore, stimulated ACTH relase could be blunted by naloxone [30] . In a previous study [9 ] , intravenous infusion of striatal acetylcholine release was stimulated by peripherally administered ceruletide via vagal afferent impulses a three times higher dose of naloxone only partially reversed morphine-induced suppression of IHT-stimu- [ 23] , and brain stem neurons in the area postrema and in the nucleus of the tractus solitarius, primarily regions lated PP release. Naloxone applied alone did not modify basal and stimulated PP release in our study and in where sensory vagal afferent fibres terminate, might be activated by CCK [24 ] . Therefore, CCK-or ceruletideothers [9, 10, 31 ] . Therefore, the opiate property of It has not yet been investigated whether endogenously bile and Na-taurodeoxycholate on exocrine pancreatic secretion and on plasma levels of secretin, pancreatic released opiates are also able to exert an inhibitory polypeptide, and gastrin in man. Scand J Gastroenterol
